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bjectives This study sought to evaluate ischemic and bleeding outcomes in patients with chronic kid-
ey disease (CKD) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
ackground Previous studies have shown that CKD is associated with poor outcomes after PCI.
owever, these studies were largely conducted before the introduction of DES and aggressive anti-
hrombotic therapy or were performed in the setting of randomized trials. With data from a con-
emporary registry, we evaluated the inﬂuence of CKD on major cardiovascular events and bleeding
omplications in unselected “real-world” patients undergoing PCI.
ethods Data from 4,791 patients enrolled in the EVENT (Evaluation of Drug Eluting Stents and
schemic Events) Registry between July 2004 and September 2005 were analyzed. Patients were
tratiﬁed into 4 groups: creatinine clearance (CrCl) 75, 50 to 75, 30 to 49 and 30 ml/min.
esults During the index hospital stay, there was a step-wise increase in bleeding complications
ith decreasing CrCl (3.3%, 5.0%, 8.8%, and 14.3%; p  0.0001 for trend). Lower CrCl was also asso-
iated with more frequent death or myocardial infarction (MI) during the initial hospital stay (p 
.001) and at 1 year (p  0.001). These ﬁndings were conﬁrmed in multivariate analyses that ad-
usted for baseline differences in demographic, clinical, and angiographic factors. Use of guideline-
ecommended medications at 1 year, including aspirin, clopidogrel, angiotensin-converting enzyme
nhibitors, and statins, also decreased with declining renal function.
onclusions Renal function is an independent and powerful predictor of bleeding and ischemic
omplications in the era of DES and contemporary antithrombotic therapy in patients undergoing
CI. The low use of guideline-recommended drugs among patients with CKD undergoing PCI might
ontribute to these adverse outcomes and warrants further evaluation. (J Am Coll Cardiol Intv
009;2:37–45) © 2009 by the American College of Cardiology Foundation
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38ore than 19 million people in the U.S. suffer from chronic
idney disease (CKD); cardiovascular disease is the major
ause of mortality in these patients (1,2). Many clinical
tudies have demonstrated that patients with CKD have
oor outcomes after percutaneous coronary intervention
PCI), including increased rates of death and myocardial
nfarction (MI) relative to patients with preserved renal
unction (3,4). However, most of these studies were per-
ormed before the introduction of drug-eluting stents
DES) and modern antithrombotic therapy (5,6). More-
ver, major cardiovascular disease trials often exclude or
imit enrollment of patients with significant kidney disease
7). As such, the clinical outcomes in this patient population
re largely unexplored yet remain relevant to the practice of
cardiology. The EVENT (Eval-
uation of Drug Eluting Stents
and Ischemic Events) registry is
an ongoing multicenter study
that aims to evaluate the out-
comes of unselected patients un-
dergoing PCI in the era of DES
(8,9) and thus provides a unique
opportunity to evaluate ischemic
and bleeding outcomes of pa-
tients with CKD after PCI in
the “real-world” setting.
Methods
A detailed description of the pa-
tient population and the design
of the EVENT registry have
been published (8). Briefly, it is
an ongoing multicenter registry
that prospectively enrolls uns-
elected patients undergoing PCI
at 42 U.S. centers. Enrollment
occurs in discrete “waves” of ap-
proximately 2,500 patients at
approximately yearly intervals.
he current analysis includes patients enrolled in the first 2
aves of the registry. Patients in whom stent implantation
as not attempted during PCI or who had undergone PCI
r cardiac surgery within the preceding 4 weeks were
xcluded. Patients underwent PCI for a variety of clinical
ndications, including ST-segment elevation myocardial
nfarction (STEMI), acute coronary syndrome (ACS), as
ell as chronic stable angina or a positive stress test. Data
oncerning patient characteristics, presentation, and treat-
ent were collected prospectively on standardized case
eport forms and submitted to the data coordinating center.
rotocol-mandated creatine kinase (CK) and creatine
inase-myocardial band (CK-MB) levels were assessed at
bbreviations
nd Acronyms
CS  acute coronary
yndrome
K  creatine kinase
K-MB  creatine kinase-
yocardial band
KD  chronic kidney
isease
rCl  creatinine clearance
ES  drug-eluting stent(s)
TI  direct thrombin
nhibitor
P  glycoprotein
I  myocardial infarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarction
LR  target lesion
evascularizationaseline and every 8 h for a minimum of 2 samples after the brocedure and assayed with each site’s clinical laboratory
nd reference values. If MI was suspected clinically at a later
oint, additional biomarkers were obtained. The institu-
ional review board of each hospital approved the facility’s
articipation in the EVENT registry. Informed consent was
btained from each participating patient. Telephone
ollow-up was performed at 6 and 12 months after the PCI
o ascertain the occurrence of major cardiovascular events.
ssessment of renal function and stratiﬁcation. Serum cre-
tinine levels were recorded at baseline for all patients. For
he purposes of this study, renal function was assessed
ccording to creatinine clearance (CrCl), which was calcu-
ated on the basis of age, gender, ideal body weight (kg), and
erum creatinine (mg/dl) with the Cockcroft-Gault equa-
ion (10). Patients were separated into 4 groups on the basis
f CrCl: 75 ml/min, 50 to 75 ml/min, 30 to 49 ml/min,
nd 30 ml/min. Because the focus of this analysis was on
enal function, patients for whom baseline CrCl could not
e calculated were excluded from the current study.
eﬁnitions. All deaths, MIs, and stent thromboses were
djudicated centrally by 2 cardiologists blinded to CrCl.
yocardial infarction was defined as elevation of CK or
K-MB at least 3 the local upper limit of normal (or CK
f CK-MB levels were not available). Among patients in
hom CK or CK-MB were elevated at baseline, an increase
f at least 2 compared with the baseline was necessary as
ell. Lesion complexity was assessed according to the
odified American College of Cardiology/American Heart
ssociation classification system (11). Target lesion revas-
ularization (TLR) was defined as any repeat percutaneous
ntervention or bypass surgery to treat recurrent stenosis of
he original target lesion. Stent thrombosis was defined as
ngiographic thrombus or subacute closure within the
tented vessel at the time of coronary angiography for
ocumented ischemia (chest pain and electrocardiographic
hanges) as well as any death not attributed to a noncardiac
ause within the first 30 days in the absence of documented
ngiographic stent patency. Bleeding was defined using
hrombolysis In Myocardial Infarction (TIMI) major and
inor criteria (12). Vascular access site complications in-
luded retroperitoneal bleeding, thrombosis of the access
essel, femoral arterial aneurysm or hematoma necessitating
urgical repair, blood transfusion, and increase in the length
f hospital stay by at least 1 day. Composite bleeding
ncluded access site complication, TIMI major and minor
leeding, and blood transfusion.
nd points. The principal end points for this study were all
ause mortality, MI, the composite of death or MI, and a
omposite of bleeding complications consisting of access site
omplications, TIMI major and minor bleeding, or blood
ransfusion during the index hospital stay. One-year out-
omes included death, MI, and the composite of death or
I. Secondary outcomes included TIMI major and minor
leeding and post-procedure length of stay during index
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39ospital stay, whereas TLR and stent thrombosis were
valuated at 1 year.
tatistical analysis. For baseline, angiographic, and procedural
haracteristics, continuous variables are described as mean 1
D and compared among CrCl groups with analysis of
ariance. Categorical variables are described as proportions and
ompared by chi-square testing. Clinical outcome and
ollow-up medication variables are reported as proportions or
ean  1 SD and compared with logistic, exact logistic, or
inear regression as appropriate with a test for trend across the
rCl categories. Time-to-event curves were constructed with
he Kaplan-Meier approach. For the analyses of the association
etween CrCl and clinical outcomes, CrCl was analyzed as a
ategorical predictor with the 4 categories defined in the
receding text, and a test for trend in categories was conducted.
n secondary models it was analyzed as a continuous log-
ransformed variable. Logistic regression analysis was used for
ll in-hospital outcomes, and the Cox proportional hazards
odel was employed for 1-year outcomes, censoring individ-
als at the last known date of event-free status. In cases where
here were 5 events in 1 or more CrCl strata, exact logistic
egression was used.
In addition to the univariate models, multivariable regres-
ion analyses were conducted (logistic or proportional haz-
rds, as appropriate) adjusting for baseline differences in
emographic, clinical, and angiographic factors. In addition
o age and gender, the analysis of bleeding complications
as further adjusted for hypertension, clinical indication for
he procedure (STEMI, ACS or other), hemoglobin, and
he use of antithrombotic agents (heparin alone, heparin
lus glycoprotein [GP] IIb/IIIa inhibitors, direct thrombin
nhibitor [DTI] alone, or heparin/DTI plus GP IIb/IIIa
nhibitors). The variables used for the adjustment in the
nalysis of 1-year ischemic outcomes (death, death or MI)
ncluded age, gender, clinical indication for the procedure
STEMI, ACS, chronic stable angina or positive stress test,
r other), presence of significant left anterior descending
rtery disease, as well as composite bleeding.
All statistical analyses were performed with SAS 8.2
SAS Institute, Cary, North Carolina). Unless specified
therwise, a 2-tailed p value of 0.05 was considered
tatistically significant.
esults
aseline characteristics. A total of 5,053 consecutive patients
ere enrolled in Waves 1 and 2 of the EVENT registry
etween July 2004 and September 2005. After excluding 262
atients with missing baseline renal function assessment, 4,791
atients constituted the study cohort. Approximately 59%
2,827) of patients had normal renal function (CrCl 75
l/min), whereas 26% (1,253) had mild renal impairment
CrCl 50 to 75 ml/min), 12% (571) had moderate renal
mpairment (CrCl 30 to 49 ml/min), and 3% (140) had severe Kenal impairment (CrCl 30 ml/min). Of the 140 patients
ith severe renal impairment, 51 (approximately 1% of the
otal sample) were dependent on renal dialysis.
On average, patients with a CrCl below 75 ml/min were
lder than those with a CrCl above 75 ml/min and were
ore likely to be female and have a history of congestive
eart failure, coronary artery bypass grafting, diabetes,
ypertension, stroke, and peripheral arterial disease. Pa-
ients with lower CrCl were less likely to be current smokers
nd to have presented with a STEMI. Other potential
ndications for PCI did not differ according to renal func-
ion. Of note, among patients with at least moderate renal
nsufficiency, 24% had only a slight increase in serum
reatinine (level between 1.5 and 2.0 mg/dl) at baseline
Table 1).
Angiographic characteristics of the study population are
isplayed in Table 2. A total of 6,655 lesions were treated in
,791 patients, with a similar number of lesions treated/
atient across groups. Approximately 15% of patients un-
erwent multivessel PCI in each group. Percutaneous cor-
nary intervention was performed more frequently in left
ain and saphenous vein graft lesions in the lowest CrCl
roup. Additionally, patients with worse renal function had
CI performed in more complex lesions (B2/C per Amer-
can College of Cardiology classification).
Procedural characteristics of the study population are sum-
arized in Table 3. Most patients received only DES. The use
f anticoagulants varied significantly among the groups (p 
.0001) as shown in Table 3. Unfractionated heparin or DTI
lone was used more frequently in patients with lower CrCl.
onversely, GP IIb/IIIa inhibitors were used less frequently in
atients with greater renal impairment. Eptifibatide was the
redominant GP IIb/IIIa inhibitor used, irrespective of renal
unction. However, use of abciximab increased as renal func-
ion worsened, (CrCl 75 ml/min, 83% eptifibatide vs. 15%
bciximab; CrCl 30 ml/min, 57% eptifibatide vs. 41%
bciximab). In patients receiving heparin, higher activated
lotting time was seen in patients with CrCl between 30 and
5 ml/min (p  0.03).
n-hospital outcomes. Impaired renal function was associ-
ted with a graded increase in both ischemic and bleeding
omplications during the index hospital stay (Table 4). Of
he 4,791 patients, 227 developed the composite end point
f bleeding complications. There was a progressive increase
n the frequency of the composite end point of death or MI
uring the index hospital stay from 5.8% to 10% with
orsening renal function (p  0.0016), driven primarily by
greater incidence of in-hospital MI among patients with
ower CrCl (p  0.002). Finally, post-procedure length of
ospital stay was greater in patients with worse renal
unction at baseline (Table 4).
ne-year outcomes. During 1 year of follow-up, 139 pa-
ients (2.9%) died and 395 (8.2%) experienced an MI. The
aplan-Meier curves for survival are displayed in Figure 1.
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40ith decreasing CrCl, there was a stepwise increase in
ortality across all groups (unadjusted p value for trend
0.0001) (Table 4). The incidence of MI also increased
ith worsening renal function (unadjusted p value for trend
.0007). Stent thrombosis (p  0.99) and repeat revascu-
arization (unadjusted p value for trend 0.51) were not
ifferent among the various groups.
Trends in cardiovascular medication usage at 6 and 12
onths showed a significant decline in use of guideline-
ecommended pharmacotherapy with decreasing CrCl
e.g., CrCl 75 ml/min vs. CrCl 30 ml/min) at 1 year,
spirin (93% vs. 73%), clopidogrel (72% vs. 63%),
ydroxymethylglutaryl-coenzyme A reductase inhibitors
86% vs. 65%), and angiotensin-converting enzyme inhibi-
ors (52% in vs. 34%) as shown in Table 5. The follow-up
ates were between 95% and 98% at 6 months and between
2% and 94% at 1 year for all CrCl groups.
ultivariable analysis. Creatinine clearance was a powerful
redictor of bleeding complications. This observation held
rue even when multiple variables including antithrombotic
se and baseline hemoglobin were progressively forced into
he model (Table 6). The multivariable-adjusted odds of
Table 1. Baseline Demographic and Clinical Characteristics
>75 ml/min
(n  2,827)
50–75 ml/
(n  1,25
Demographic
Age (yrs), mean  SD 58.86 9.57 70.59 8.6
Weight (kg) 95.13 18.97 79.51 13.
BMI (kg/m2) 31.54 5.94 27.78 4.7
Male 76.7% 63.8%
Creatinine 1.5–2.0 (mg/dl) 0.5% 7.4%
Hgb (g/dl), mean  SD 14.56 7.46 13.69 6.3
Medical history
Diabetes 33.8% 31.0%
Hypertension 74.5% 79.0%
Hyperlipidemia 72.3% 75.1%
Current smoking 31.1% 16.2%
Congestive heart failure 6.5% 11.8%
MI 37.3% 37.0%
PCI 35.5% 37.2%
CABG 18.2% 26.3%
Indication for PCI
Chronic stable angina 19.8% 22.6%
Positive stress test 36.6% 37.4%
NSTE-ACS 34.7% 31.8%
STEMI 6.5% 3.9%
Other 9.9% 12.4%
p values are based on chi-square test or F test as appropriate.
BMI bodymass index; CABG coronary artery bypass grafting; Hgb hemoglobin; MImyo
coronary intervention; STEMI ST-segment elevation myocardial infarction.leeding complications were more than 3 as high in the t30 ml/min CrCl group compared with the referent group
f CrCl 75 ml/min (odds ratio: 3.23, 95% confidence
nterval: 1.72 to 6.04) (Table 6).
At 1 year, renal dysfunction emerged as an independent
redictor of mortality after adjustment for the risk factors
isted earlier (Table 6). The composite of death and MI also
ncreased across all CrCl groups (p  0.0001). Individuals
ith CrCl 30 ml/min had more than 5 the risk of dying
han those with CrCl 75 ml/min (multivariable-adjusted
azard ratio: 5.35, 95% confidence interval: 2.86 to 10.02).
oticeably, TLR did not increase with renal dysfunction.
nalysis of CrCl as a continuous, log-transformed predictor
emonstrated similar findings for in-hospital and 1-year
utcomes (data not shown).
iscussion
ur study generated several important results. Renal insuf-
ciency was associated with increased in-hospital death and
I as well as bleeding complications, even after adjustment
or other clinical factors that could potentially confound
inine Clearance
p Value
30–49 ml/min
(n  571)
<30 ml/min
(n  140)
76.32 8.17 72.07 12.61 0.0001
71.09 14.34 72.69 18.62 0.0001
26.09 4.84 26.30 5.95 0.0001
44.3% 49.3% 0.0001
25.0% 22.1% 0.0001
12.54 2.00 11.90 2.25 0.0001
34.7% 47.1% 0.0013
85.6% 94.3% 0.0001
73.7% 71.0% 0.2675
12.2% 14.4% 0.0001
19.2% 32.4% 0.0001
41.4% 39.9% 0.2505
38.1% 43.9% 0.1417
27.4% 30.9% 0.0001
0.0052
18.7% 17.9%
30.5% 30.7%
38.5% 37.1%
3.7% 0.0%
15.2% 24.3%
infarction; NSTE-ACS non–ST-segment elevation acute coronary syndrome; PCI percutaneousCreat
min
3)
4
85
6
5
cardialhese associations. One-year ischemic outcomes including
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41eath and nonfatal MI also increased in a step-wise fashion
s CrCl decreased. Despite these important clinical out-
omes, renal dysfunction was not associated with an in-
reased risk of stent-specific events, including stent throm-
osis or clinical restenosis (i.e., TLR). We also found that
uideline-recommended medications were used less fre-
Table 2. Angiographic Characteristics (Lesion-Based)
Creat
>75 ml/min
(n  3,939)
50–75 ml/
(n  1,71
Target vessel
LAD 35.7% 34.5%
Circumﬂex 23.2% 22.3%
RCA 34.2% 31.9%
LMCA 1.2% 1.5%
SVG 5.8% 9.9%
Lesions treated per patient 1.40 0.65 1.37 0.6
Lesion classiﬁcation*
A 12.1% 12.3%
B1 33.9% 31.5%
B2 32.4% 34.2%
C 21.6% 22.0%
Total occlusion 6.8% 5.0%
Bifurcation lesion 12.4% 11.1%
Angiographic thrombus 12.4% 9.3%
p values are based on chi-square test or F-test as appropriate. *Lesion based on American College o
LAD left anterior descending artery; LMCA left main coronary artery; RCA right coronary a
Table 3. Procedural Characteristics
>75 ml/min
(n  2,827)
50–75 m
(n  1
Stents
DES  BMS 3.5% 4.5
DES only 89.5% 87.6
BMS only 6.1% 6.9
Antithrombotic medications
Heparin alone 15.5% 18.2
LMWH alone 0.1% 0.2
DTI alone 27.5% 30.1
Heparin  GP IIb/IIIa 41.4% 38.2
LMWH  GP IIb/IIIa 1.5% 0.4
DTI  GP IIb/IIIa 2.2% 1.6
Other* 11.8% 11.3
Peak ACT (s)†
Heparin alone peak ACT(s) 275 (244–314) 281 (252
Heparin  GP IIb/IIIa (s) 250 (223–285) 260 (229
DTI alone peak ACT(s) 330 (298–372) 342 (303
DTI  GP IIb/IIIa peak ACT (s) 352 (332–389) 375 (361
p values are based on chi-square or F test as appropriate. *Other medication combinations not listeBMS bare-metal stent(s); DES drug-eluting stent(s); DTI direct thrombin inhibitor; GP glycoprotuently as renal function worsened. We found that, consis-
ent with other reports, more than 40% of patients under-
oing PCI have impaired renal function. We also found that
lmost one-fourth of patients with significant renal insuffi-
iency undergoing PCI have only a mild increase in serum
reatinine (between 1.5 to 2.0 mg/dl), emphasizing the
learance, All Lesions
p Value
30–49 ml/min
(n  815)
<30 ml/min
(n  187)
0.0001
36.2% 28.3%
24.4% 22.5%
28.3% 32.6%
2.5% 3.7%
8.6% 12.8%
1.43 0.67 1.36 0.63 0.2818
0.0004
10.0% 6.4%
32.0% 24.6%
32.8% 42.8%
25.2% 26.2%
4.7% 4.3% 0.0098
11.8% 15.5% 0.2776
10.4% 9.1% 0.0038
logy/American Heart Association lesion classification.
VG saphenous vein graft.
atinine Clearance
p Value
30–49 ml/min
(n  571)
<30 ml/min
(n  140)
0.3809
4.2% 5.0%
87.1% 84.3%
7.5% 8.6%
0.0001
20.3% 29.3%
0% 0
32.9% 33.6%
33.9% 25.7%
0.5% 0
2.1% 1.4%
10.2% 10.0%
285 (253–328) 253 (186–315) 0.0346
260 (233–296) 252 (216–305) 0.0071
348 (311–390) 305 (270–370) 0.0582
334 (323–409) N/A 0.6644
. †Activated clotting time (ACT) values are presented as median values with interquartile ranges.inine C
min
4)
3
f CardioCre
l/min
,253)
%
%
%
%
%
%
%
%
%
%
–325)
–294)
–381)
–400)
d aboveein; LMWH low-molecular weight heparin; PCI percutaneous coronary intervention.
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42dvantage of using CrCl over serum creatinine, as the
osage of certain antithrombotic medications need to be
djusted on the basis of CrCl.
Table 4. Clinical Outcomes
>75 ml/min
(n  2,827)
50–7
(n 
In-hospital
Death 0.1%
MI 5.7%
Death or MI 5.8%
Composite bleeding* 3.3%
TIMI major 0.2%
TIMI minor 0.8%
Access site complications† 1.9%
Transfusion 1.6%
Post-procedure length of
stay (days), mean  SD (n)
1.56 2.37 (2,826) 1.63
1-yr
Death 1.5%
MI 7.2%
Death or MI 8.5% 1
Stent thrombosis 1.3%
Any repeat revascularization 11.9% 1
Target lesion
revascularization
4.2%
Nontarget lesion
revascularization
7.4%
Death or MI or repeat
revascularization
18.0% 2
pvalues arebasedon linear, logistic, or exact logistic regressionwith1variable for 4 creatinine clearan
of access site complication, TIMI major, TIMI minor bleeding and transfusion. †Access site complica
hematoma necessitating surgical repairs.
MImyocardial infarction; TIMI Thrombolysis In Myocardial Infarction.Figure 1. Kaplan-Meier Survival Curve for 1-Year Deathleeding complications in CKD. Renal dysfunction has been
hown to be a risk factor for bleeding complications in
atients undergoing PCI in the setting of STEMI as well as
eatinine Clearance
p Value
in
)
30–49 ml/min
(n  571)
<30 ml/min
(n  140)
0.9% 0.0% 0.0206
8.2% 10.0% 0.0023
8.4% 10.0% 0.0016
8.8% 14.3% 0.0001
1.2% 0.0% 0.5587
1.2% 0.0% 0.0567
3.0% 0.7% 0.3121
6.3% 13.6% 0.0001
,253) 2.19 2.73 (571) 2.49 2.84 (140)
5.8% 13.6% 0.0001
10.7% 11.4% 0.0007
15.1% 22.1% 0.0001
1.1% 1.4% 0.9906
9.5% 11.4% 0.5111
3.3% 4.3% 0.7045
6.3% 6.4% 0.7491
21.5% 27.9% 0.0003
ps. Post-procedure lengthof stay is basedon simple regression. *Compositebleeding composite
retroperitoneal bleeding, thrombosis of access vessel, femoral arterial aneurysm orCr
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43CS (13,14). Few previous studies have demonstrated a
inear increase in bleeding after PCI with a concomitant
ecrease in CrCl (15,16). However, these analyses were
ither performed in the setting of randomized controlled
rials or were in the era of bare-metal stents and non-
ontemporary antithrombotic therapy, in contrast to our
tudy, which was performed in the real-world setting.
In our study, patients with CrCl 30 to 49 ml/min had
igher peak activated clotting times and were particularly
ore susceptible to hemorrhagic complications. Whereas
here has been increasing emphasis on proper medication
osing in patients with renal insufficiency, one possible
xplanation for our finding is that moderate degrees of renal
nsufficiency might have been overlooked in some patients.
n particular, estimation of renal function on the basis of
erum creatinine alone might have led to inadvertent over-
osing of antithrombotic medications that are renally me-
abolized, including GP IIb/IIIa inhibitors such as eptifi-
atide. Recently, Alexander et al. (17,18) reported that renal
ysfunction was an independent predictor of excessive
osing of heparins and GP IIb/IIIa inhibitors and of TIMI
Table 5. Follow-Up Medication Usage
CrCl >75 ml/min CrCl 50–75 ml/min
At 6 months (n  2,682) (n  1,215)
Aspirin 92.6% 89.7%
Statins 84.6% 81.3%
ACE inhibitor 50.7% 47.5%
Clopidogrel 84.3% 80.7%
At 12 months (n  2,598) (n  1,183)
Aspirin 92.7% 90.4%
Statins 85.8% 83.8%
ACE Inhibitor 51.8% 47.8%
Clopidogrel 71.9% 68.6%
Denominator patients who were followed up at 6 months and 12 months, respectively. p values
ACE angiotensin-converting enzyme; CrCl creatinine clearance; Statins hydroxymethylgluta
Table 6. Multivariate Analysis
Outcome CrCl 50–75 ml/min CrCl 30–49 ml/min
In-hospital events
MI 1.089 [0.800–1.483] 1.169 [0.771–1.772]
Death or MI 1.096 [0.807–1.490] 1.166 [0.771–1.762]
Composite bleeding 1.179 [0.807–1.723] 1.607 [1.014–2.545]
Cumulative 12-month events
Death 1.714 [1.069–2.747] 2.360 [1.346–4.140]
Death or MI 1.315 [1.043–1.659] 1.488 [1.083–1.989]
TLR 1.321 [0.916–1.905] 0.998 [0.570–1.749]CI confidence interval; CrCl creatinine clearance; OR odds ratio; MImyocardial infarction; TLR tajor bleeding among patients presenting with ACS and
hat this practice was more common in women than in men.
he appropriate dosing of heparin in patients with CKD
as not been studied very well (19). Although excess dosing
f antithrombotic agents could also have played a role in
ncreased bleeding complications of patients with CKD, we
ere unable to prove this association in the EVENT
egistry, because doses of GP IIb/IIIa antagonists were not
ystematically collected in our study cohort. It is also likely
hat patients with CKD are at increased risk of bleeding,
ven in the absence of dosing errors. For example, renal
nsufficiency has been associated with several abnormalities
f primary hemostasis, particularly platelet dysfunction
haracterized by decreased release of adenosine triphosphate
nd decreased serotonin content in dense granules (20).
Blood transfusions, even after adjusting for baseline
emoglobin, were more often administered in patients with
ecreased renal function, a finding that could be related to
lower threshold for transfusion in patients with severe
KD. Previous studies have shown an increase in blood
ransfusions in patients with CKD after PCI (3,21).
CrCl 30–49 ml/min CrCl <30 ml/min
(n  558) (n  133) p Value
85.3% 76.7% 0.0001
79.2% 69.9% 0.0001
43.9% 39.8% 0.0001
78.0% 67.7% 0.0001
(n  531) (n  132) p Value
86.3% 72.7% 0.0001
81.4% 65.2% 0.0001
39.9% 34.1% 0.0001
65.0% 62.9% 0.0001
d on logistic regression with 1 variable for 4 creatinine groups.
zyme A reductase inhibitors.
Adjusted OR (95% CI)
CrCl <30 ml/min
Multivariate
p Value
Minus Continuous
log CrCl p Value
1.615 [0.872–2.991] 0.1727 1.150 [0.879–1.504] 0.3073
1.584 [0.855–2.933] 0.1839 1.151 [0.882–1.503] 0.3004
3.140 [1.735–5.682] 0.0004 1.517 [1.166–1.973] 0.0019
5.357 [2.863–10.021] 0.0001 1.692 [1.338–2.093] 0.0001
2.192 [1.464–3.281] 0.0001 1.374 [1.167–1.617] 0.0001
1.213 [0.516–2.847] 0.5753 1.070 [0.769–1.489] 0.6866are basearget lesion revascularization.
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44schemic outcomes in CKD. Our study showed a marked
ncrease in in-hospital and 1-year cardiovascular events after
CI as renal function worsened. Other smaller and retro-
pective studies have shown increased mortality and MI
ithin 1 year after PCI with DES (22), even when the
egree of renal insufficiency is mild (23). However, the large
opulation of patients with varying degrees of renal dys-
unction in our study provides greater power to examine a
roader spectrum of outcomes, including death as well as
ncreased long-term risk of MI, in this patient population.
One of the strengths of our study was that systematic
ollection of pre- and post-procedure cardiac markers al-
owed for reliable detection of periprocedural ischemic
vents without ascertainment bias. Indeed, we observed a
tepwise increased incidence of periprocedural MI with
orsening renal function. Of note, the use of GP IIb/IIIa
ntagonists decreased with worsening renal function, which
ould have played a role in the increased incidence of
ost-procedural MI in patients with CKD, given their
roven role in reducing these complications (24).
Studies have shown that the need for repeat revascular-
zation in patients with CKD has decreased with the advent
f DES (21,25). However, a recent study showed that the
eed for repeat revascularization increases with renal dys-
unction, even in patients receiving DES (26). Renal failure
as also been implicated as an independent predictor of
tent thrombosis with DES, being second only to premature
iscontinuation of clopidogrel (27). However, repeat revas-
ularization or stent thrombosis was not found to be
ncreased in patients with CKD at 1-year follow-up in our
nalysis, questioning earlier findings.
Recently, more emphasis is being laid on bleeding com-
lications as a determinant of mortality in patients after
CI. However, our results indicate that even after correcting
or bleeding complications, outcomes remain worse in
atients with lower CrCl. Therefore, in patients with CKD,
dditional factors attributable to CKD as well as underuse of
ecommended cardioprotective medications could account
or worse outcomes. It has been reported that cardioprotec-
ive medications are less often used in the management of
atients with CKD (28). To our knowledge, our study is the
rst to show the paradoxical underuse of cardioprotective
rugs after PCI in a CKD population. Use of medications
uch as aspirin, clopidogrel, statins, and angiotensin-
onverting enzyme inhibitors decreased in a step-wise fash-
on with the drop in CrCl at 1 year. Although further
tudies are needed to evaluate the safety and efficacy of
uideline-recommended therapies in patients with CKD, it
eems paradoxical that cardiovascular pharmacotherapy is
eing underused in patients who might benefit the most.
imitations. Although our data were collected prospectively,
he current analysis was not specified prospectively. Conse-
uently, the data collected did not include whether the
nticoagulants were dosed on the basis of CrCl or serumreatinine or whether renal function was considered at all in
ose selection. Similarly, transfusion was a major compo-
ent of the composite bleeding end point, and we did not
ollect data regarding indication for transfusion. We had
imited power to evaluate some end points such as stent
hrombosis and to evaluate dialysis patients separately.
imilarly, we did not collect information on post-procedure
enal failure or dialysis as complications of PCI.
The Cockcroft-Gault equation was used for estimation of
rCl. This formula might overestimate CrCl in obese
atients. Although the number of patients who received
are-metal stents was small, we did not compare the
utcomes of patients receiving DES with those of patients
eceiving bare-metal stents.
onclusions
enal dysfunction, as determined by CrCl, is a powerful
ndependent predictor of in-hospital bleeding complications
nd 1-year ischemic events including death and nonfatal MI
n the current era of DES and antithrombotic therapy.
aradoxically, suboptimal long-term use of guideline-
ecommended cardiovascular pharmacotherapy is observed
n patients with CKD after PCI. With the aging of the
opulation and the increase in the number of patients with
KD, the need for their inclusion in ongoing and future
ardiovascular trials to determine whether current therapeu-
ic approaches are effective is as great as ever.
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